Zur Rose completes rare at-market rights issue at 10.7% discount
Zur Rose, the Swiss online pharmacy, has completed its Sfr200m ($200.8m) at-market rights issue to fund the acquisition of a German e-commerce platform, following the sale of a rump placement on Wednesday evening.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts